GR1003861B - Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. - Google Patents

Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.

Info

Publication number
GR1003861B
GR1003861B GR20000100470A GR2000100470A GR1003861B GR 1003861 B GR1003861 B GR 1003861B GR 20000100470 A GR20000100470 A GR 20000100470A GR 2000100470 A GR2000100470 A GR 2000100470A GR 1003861 B GR1003861 B GR 1003861B
Authority
GR
Greece
Prior art keywords
present
anxiety
neurosteroids
formula
compounds
Prior art date
Application number
GR20000100470A
Other languages
English (en)
Inventor
Original Assignee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by filed Critical
Priority to GR20000100470A priority Critical patent/GR1003861B/el
Priority to PCT/GR2001/000048 priority patent/WO2002053577A2/en
Priority to AU2002217353A priority patent/AU2002217353A1/en
Priority to US10/250,334 priority patent/US7064116B2/en
Publication of GR1003861B publication Critical patent/GR1003861B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

παρούσα εφεύρεση αναφέρεται σε νέα ανάλογα στεροειδών τα οποία επιδρούν στον ιοντοφόρο σύμπλεγμα υποδοχέας γ-αμινοβουτυρικού οξέος-κανάλι χλωρίου καθώς επίσης και μεθόδους για τη σύνθεση αυτών και εφαρμογή τους σαν αναισθητικά, για την αντιμετώπιση του stress, άγχους, αυπνίας, επιληψίας , PMS, PDN και για τη βελτίωση ή πρόληψη επεισοδίων άγχους, μυικής τάσης και κατάθλιψης οι οποίες είναι καταστάσεις που απαντώνται σε ασθενείς που υποφέρουν απο διαταραχές του κεντρικού νευρικού συστήματος. Η παρούσα εφεύρεση περιλαμβάνει ενώσεις του τύπου (Ι) όπου τα R1,R2,R3,R4,R5 προσδιορίζονται στην Περιγραφή της εφεύρεσης Επίσης μέρος της εφεύρεσης αποτελούν και φαρμακοτεχνικές μορφές που περιλαμβάνουν μία ή και περισσότερες απο τις ενώσεις του τύπου (Ι). ΰ
GR20000100470A 2000-12-29 2000-12-29 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. GR1003861B (el)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GR20000100470A GR1003861B (el) 2000-12-29 2000-12-29 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
PCT/GR2001/000048 WO2002053577A2 (en) 2000-12-29 2001-12-21 Gabaa modulating neurosteroids
AU2002217353A AU2002217353A1 (en) 2000-12-29 2001-12-21 Gabaa modulating neurosteroids
US10/250,334 US7064116B2 (en) 2000-12-29 2001-12-21 GABAA modulating neurosteroids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20000100470A GR1003861B (el) 2000-12-29 2000-12-29 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.

Publications (1)

Publication Number Publication Date
GR1003861B true GR1003861B (el) 2002-04-11

Family

ID=10944475

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000100470A GR1003861B (el) 2000-12-29 2000-12-29 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.

Country Status (4)

Country Link
US (1) US7064116B2 (el)
AU (1) AU2002217353A1 (el)
GR (1) GR1003861B (el)
WO (1) WO2002053577A2 (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2260052A4 (en) * 2008-02-26 2013-01-16 Univ Emory STEROIDANALOGA FOR NEUROPROTEKTION
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CZ302050B6 (cs) * 2009-08-04 2010-09-15 Ústav organické chemie a biochemie, Akademie ved CR, v.v.i. 3alfa-Hydroxy-21ksí,22-oxido-21-homo-5alfa-pregnan-20-on, zpusob jeho výroby a jeho použití
US20130303500A1 (en) * 2010-07-30 2013-11-14 Medexis S.A. Compounds and methods for treating neoplasia
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP3572417B1 (en) 2011-10-14 2025-12-17 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
HUE039057T2 (hu) 2012-12-18 2018-12-28 Univ Washington Kezelési eljárásokban alkalmazható neuroaktív 19-alkoxi-17-szubsztituált szteroidok
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
PT2968369T (pt) 2013-03-13 2018-12-05 Sage Therapeutics Inc Esteroides neuroativos e métodos para o seu uso
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP2986624B1 (en) 2013-04-17 2020-03-25 Sage Therapeutics, Inc. 19-nor neuroactive steroids for methods of treatment
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
AU2014308621C1 (en) 2013-08-23 2022-01-06 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
CN117024501A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE071964T2 (hu) 2015-07-06 2025-10-28 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
CA2991311C (en) 2015-07-06 2025-05-06 Sage Therapeutics, Inc. OXYSTEROLS AND THEIR METHODS OF USE
KR20240157128A (ko) 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430942A (en) * 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
WO1994027608A1 (en) * 1993-05-24 1994-12-08 Cocensys, Inc. Methods and compositions for inducing sleep
WO1996040043A2 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430942A (en) * 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
WO1994027608A1 (en) * 1993-05-24 1994-12-08 Cocensys, Inc. Methods and compositions for inducing sleep
WO1996040043A2 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERCOLI ET AL: "Sugli Acidi Biliari e loro Derivati. Nota IV - Un Nouvo Metodo di Demolizione Graduale. Sua Applicazione alla Degradazione dell'Acido Litocolico", FARMACO., vol. 6, 1951, SOCIETA CHIMICA ITALIANA, PAVIA., IT, pages 547, XP001025589, ISSN: 0014-827X *
PETTIT G R ET AL: "BUFADIENOLIDES. 13. CONVERSION OF 3BETA-HYDROXY-17-OXOANDROST-5-ENE TO 3BETA-ACETOXY-5BETA,14ALPHA-BUFA-20,22-DIENOLIDE", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 36, no. 21, 22 October 1971 (1971-10-22), pages 3207 - 3211, XP002029626, ISSN: 0022-3263 *

Also Published As

Publication number Publication date
US7064116B2 (en) 2006-06-20
US20050176976A1 (en) 2005-08-11
WO2002053577A3 (en) 2002-10-10
AU2002217353A1 (en) 2002-07-16
WO2002053577A2 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
GR1003861B (el) Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
MXPA05010630A (es) Compuestos de benzopirano utiles para tratar estados inflamatorios.
TW200634016A (en) Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors
ATE463247T1 (de) Bupropion metaboliten zur behandlung von angstzuständen
YU45403A (sh) Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
TNSN07021A1 (fr) Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
EP1165086A4 (en) BUPROPION METABOLITES AND METHOD FOR THE PRODUCTION AND USE THEREOF
IL146403A0 (en) Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
NZ544591A (en) Pyrrolodihydroisoquinolines as PDE10 inhibitors
IL159300A0 (en) Prodrugs of gaba analogs, compositions and uses thereof
MX2007013263A (es) Novedosos derivados oxadiazol y su uso medico.
IN2006KO01346A (el)
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
BR9913701A (pt) ácidos alquil pirrolidina-3-carboxìlicos ramificados
ATE348831T1 (de) Diazabicyclische biarylderivate
ATE289310T1 (de) Heteroaryl-diazabicycloalkanderivaten als cns- modulatoren
DE60309740D1 (de) 1,4-dizabicyclo(3,2,2)nonane derivative, verfahren zur ihre herstellung und therapeutical verwendung
DK1406900T3 (da) Hidtil ukendte forbindelser, fremstilling og anvendelse deraf
TW200504045A (en) Benzopyran compounds for use in the treatment and prevention of inflammation related conditions
WO2002042256A3 (en) N-alkylated gaba compounds, processes for their preparation and their use as medicaments
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
MY129575A (en) Methods, kits and compositions for using pyrrole derivatives againts anxiety
BR0011039A (pt) Análogos de gaba substituìdos com 3-heteroarilalquila
WO2001080845A3 (en) (2-aminoethyl) oxime derivatives for the treatment of depression